XPC and cancer: Other studies have identified the XPC gene to be changed after treatment [32], and that genetic variation may influence the risk of recurrence after treatment for malignant neoplasms [33], but little is known about the effect of such genetic variants on docetaxel and/or gefitinib sensitivity, and further studies are needed to clarify this.